AstraZeneca sets the ambition to achieve a total turnover of $80 billion by 2030 and achieve sustainable growth after 2030

Forward-Looking Statements

In order to benefit, among other things, from the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereinafter ‘the Group’) provides the following cautionary statement:

This document contains certain forward-looking statements relating to the Group’s operations, performance and financial condition, including, among other things, statements regarding expected or targeted revenues, margins, earnings per share or other financial or other measures (including the financial Ambition Statements described in this announcement ). Although the Group believes that its expectations and objectives are based on reasonable assumptions and has used common forecasting methods used in the pharmaceutical industry and risk-adjusted projections for individual medicines (which take into account the likelihood of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), all forward-looking statements by their nature involve risks and uncertainties and may be affected by factors that could cause actual outcomes and results differ materially from those predicted. The forward-looking statements reflect the knowledge and information available as of the date of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies forward-looking statements by using the words “anticipates,” “believes,” “expects,” “intends” and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, some of which are beyond the Group’s control, include:

– The risk of failure or delay in pipeline delivery or new drug launches;

– the risk of not meeting legal or ethical requirements for the development or approval of medicinal products;

– the risk of failures or delays in the quality or execution of the Group’s commercial strategies;

– the risk of pricing, affordability, access and competitive pressure;

– the risk that the supply of compliant, quality medicines is not kept up to standard;

– the risk of illegal trafficking of the Group’s medicines;

– the impact of dependence on third party goods and services;

– the risk of information technology or cybersecurity failure;

– the risk of failure of critical processes;

– the risk that data is not collected and managed in accordance with legal and regulatory requirements and strategic objectives;

– the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce;

– the risk of not meeting legal or ethical expectations regarding environmental impacts, including climate change;

– the risk that the safety and efficacy of marketed medicinal products are questioned;

– the risk of an adverse outcome of lawsuits and/or government investigations;

– intellectual property risks for the Group’s products;

– the risk that the strategic plans are not realized or that the objectives or expectations are not met;

– the risk of financial control failure or the occurrence of fraud;

– the risk of an unexpected deterioration in the Group’s financial position;

– the impact that global and/or geopolitical events may have (or continue to have) on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition.

No assurances can be given that the conditions to closing the proposed transaction with Fusion will be satisfied on the expected timetable, or at all, or that “FPI-2265” (Ac225-PSMA I&T) or any combination product will receive the necessary resources will receive. regulatory approvals or prove commercially successful if approved. There can be no assurances that the conditions to closing the proposed transaction with Amolyt Pharma will be satisfied within the expected timeframe, or at all, or that eneboparatide (“AZP-3601”) will receive necessary regulatory approvals will be or will appear to be approved. commercially successful if approved.

Leave a Reply

Your email address will not be published. Required fields are marked *